Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial

Hindricks, Gerhard; Táborský, Miloš; Glikson, Michael; Heinrich, Ullus; Schumacher, Burghard; Katz, Amos; Brachmann, Johannes; Lewalter, Thorsten; Goette, Andreas; Block, Michael S.; Kautzner, Josef; Sack, Stefan; Husser, Daniela; Piorkowski, Christopher; Søgaard, Peter

doi:10.1016/s0140-6736(14)61176-4

Cited by 649 publications

(601 citation statements)

References 31 publications

Supporting

Mentioning

548

Contrasting

Unclassified

Order By: Relevance

“…Dotyczy to systemu CardioMems (badaniem objęto 550 osób z HFpEF oraz HFrEF) [628], a także metody wykorzystanej w badaniu IN-TIME (badaniem objęto 664 pacjentów z HFrEF) [630]. Zastosowanie obu systemów można rozważyć u wybranych chorych z HF (patrz tabele z zaleceniami).…”

Section: Obserwacja Odległa I Monitorowanieunclassified

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Ponikowski

Voors

Anker³

et al. 2016

Kardiol Pol

460

446

View full text Add to dashboard Cite

Section: Obserwacja Odległa I Monitorowanieunclassified

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Ponikowski

Voors

Anker³

et al. 2016

Kardiol Pol

460

446

View full text Add to dashboard Cite

“…Recently, the PREDICT-RM trial demonstrated reductions in all-cause rehospitalization and all-cause mortality in a large cohort of patients after new ICD implantation who underwent RM during follow-up. 6 In the IN-TIME study, Hindricks et al 7 randomized 716 patients with left ventricular dysfunction who received an ICD (with or without CRT) to automatic, daily, implant-based telemonitoring vs. conventional followup in a single-blinded design. After one year, patients under RM had a lower composite score of all-cause mortality, admission for HF, change in NYHA class, and patient global self-assessment.…”

Section: Discussionmentioning

confidence: 99%

A link to better care: The effect of remote monitoring on long-term adverse cardiac events in a propensity score-matched cohort

Portugal¹,

Cunha²,

Valente³

et al. 2017

Revista Portuguesa de Cardiologia

View full text Add to dashboard Cite

Aims: There are conflicting data regarding the clinical benefits of device-based remote monitoring (RM). We sought to assess the effect of device-based RM on long-term clinical outcomes in recipients of implantable cardioverter-defibrillators (ICDs). Methods: We assessed the incidence of adverse cardiac events, overall mortality and device therapy efficacy and safety in a propensity score-matched cohort of patients under RM compared to patients under conventional follow-up. Data on hospitalizations, mortality and cause of death were systematically assessed using a nationwide healthcare platform. The primary outcome was time to a composite outcome of first hospital admission for heart failure or cardiovascular death. Results: Of a total of 923 implantable device recipients, 164 matched patients were identified (84 under RM, 84 under conventional follow-up). The mean follow-up was 44 months (range 1-123). There were no significant differences regarding baseline characteristics in the matched cohorts. Patients under RM had a significantly lower incidence of the primary outcome (hazard ratio [HR] 2174-2049Document downloaded from http://www.elsevier.es, day 24/05/2017. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. G. Portugal et al. Conclusion:In a propensity score-matched cohort of ICD recipients with long-term follow-up, RM was associated with a lower rate of a combined endpoint of hospital admission for heart failure or cardiovascular death. © 2017 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights reserved. (HR 0,53; IC 0,04; p=0,066). Não se observaram diferenças entre grupos relativamente a terapêuticas apropriadas (MR versus seguimento convencional; 8,1 versus 8,2%, p=NS) ou terapêuticas inapropriadas (6,8 versus 5,0%, p=NS). Conclusão: Numa amostra emparelhada por propensity score de portadores de CDI, a MR associou-se a uma menor incidência de um evento composto de internamento por IC ou morte cardiovascular a longo prazo. PALAVRAS-CHAVE

show abstract

“…The MORE CARE randomized trial revealed a median 27-day reduction in delay from actionable event detection to medical decision in the device group with remote control compared to a control group without remote data transmission [63]. The IN-TIME randomized trial recently demonstrated that automatic, daily, multiparameter telemonitoring is associated with improved clinical outcome for patients with heart failure, with a significant reduction in all-cause mortality [67]. This observation requires confirmation in additional controlled trials.…”

Section: Remote Monitoringmentioning

confidence: 99%

Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes

Boriani

Biagini

Ziacchi

et al. 2018

Nucleus

View full text Add to dashboard Cite

Lamin A/C gene mutations can be associated with cardiac diseases, usually referred to as ‘cardiolaminopathies’ characterized by arrhythmic disorders and/or left ventricular or biventricular dysfunction up to an overt picture of heart failure. The phenotypic cardiac manifestations of laminopathies are frequently mixed in complex clinical patterns and specifically may include bradyarrhythmias (sinus node disease or atrioventricular blocks), atrial arrhythmias (atrial fibrillation, atrial flutter, atrial standstill), ventricular tachyarrhythmias and heart failure of variable degrees of severity. Family history, physical examination, laboratory findings (specifically serum creatine phosphokinase values) and ECG findings are often important ‘red flags’ in diagnosing a ‘cardiolaminopathy’. Sudden arrhythmic death, thromboembolic events or stroke and severe heart failure requiring heart transplantation are the most dramatic complications of the evolution of cardiolaminopathies and appropriate risk stratification is clinically needed combined with clinical follow-up. Treatment with cardiac electrical implantable devices is indicated in case of bradyarrhythmias (implant of a device with pacemaker functions), risk of life-threatening ventricular tachyarrhythmias (implant of an ICD) or in case of heart failure with wide QRS interval (implant of a device for cardiac resynchronization). New technologies introduced in the last 5 years can help physicians to reduce device-related complications, thanks to the extension of device longevity and availability of leadless pacemakers or defibrillators, to be implanted in appropriately selected patients. An improved knowledge of the complex pathophysiological pathways involved in cardiolaminopathies and in the determinants of their progression to more severe forms will help to improve clinical management and to better target pharmacological and non-pharmacological treatments.

show abstract

Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial

Cited by 649 publications

References 31 publications

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

A link to better care: The effect of remote monitoring on long-term adverse cardiac events in a propensity score-matched cohort

Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes

Contact Info

Product

Resources

About